A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants

Pediatrics

Volumn 103, Issue 2, 1999, Pages 414-421

  Baker, James W ^a,e   Mellon, Michael ^a   Wald, Jeffrey ^b   Welch, Michael ^c   Cruz Rivera, Mario ^d   Walton Bowen, Karen ^d  

^a KAISER PERMANENTE   (United States)

^b Kansas City Allergy and Asthma Associates   (Chile)

^c ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^d Clinical Research Astra USA Incorporated   (United States)

^e NONE   (United States)

Author keywords

Asthma; Budesonide; Children; Corticosteroids

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOTROPIN; PLACEBO;

ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; METERED DOSE INHALER; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0032990025     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.103.2.414     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Asthma mortality and hospitalization among children and young adults, United States, 1990-1993. MMWR. 1996;45:350-353
2. Hartert TV, Windom HH, Peebles RS Jr., Freidhoff LR, Togias A. Inadequate outpatient medical therapy tor patients with asthma admitted to two urban hospitals. Am J Med. 1996;100:386-394
3. National Institutes of Health, National Heart, Lung and Blood Institute. Highlights of the Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health. NIH Publication No. 97-4051 A, May 1997
4. Bisgaard H, Munck SL, Nielsen JP, Petersen W, Ohlsson SV. Inhaled budesonide for treatment of recurrent wheezing in early childhood. Lancet. 1990;336:649-651
5. Noble V, Ruggins NR, Everard ML, Milner AD. Inhaled budesonide for chronic wheezing under 18 months of age. Arch Dis Child. 1992;67: 285-288
6. Connett GJ, Warde C, Wooler E, Lenney W. Use of budesonide in severe asthmatics aged 1-3 years. Arch Dis Child. 1993;69:351-355
7. Maayan C, Itzhaki J, Bar-Yishay E, Gross S, Tal A, Godfrey S. The functional response of infants with persistent wheezing to nebulized beclomethasone dipropionate. Pediatr Pulmonol. 1986;2:9-14
8. Webb MSC, Milner AD, Hiller EJ, Henry RL. Nebulized beclomethasone dipropionate suspension. Arch Dis Child. 1986;61:1108-1110
9. Storr J, Lenney C, Lenney W. Nebulized beclomethasone dipropionate in preschool asthma. Arch Dis Child. 1986;61:270-273
10. Godfrey S, Arital A, Rosler A, et al. Nebulized budesonide in severe infantile asthma. Lancet. 1987;ii:851-852
11. Hultquist C. Nebulised budesonide in severe childhood asthma. Lancet. 1989;i:380
12. Nikander K. A Controlled Case-report Study in Budesonide Nebulising Suspension. Oxford, England: Oxford Clinical Communications; 1989: 29-31
13. Ilangovan P, Pedersen S, Godfrey S, Nikander K, Noviski N, Warner JO. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child. 1993;68:356-359
14. Grimfeld A, Lesbros D and Study Group, Ostinelli J, Caswell C. Long term study of nebulised budesonide in young children with moderate to severe asthma. Eur Respir J. 1994;7:27S
15. Wennergren G, Nordvall SL, Hedlin G, Moller C, Wille S, Asbrink Nilsson E. Nebulised budesonide for the treatment of moderate to severe asthma in infants and toddlers. Acta Paediatr. 1996;85: 183-189
16. de Blic J, Delacourt C, Le Bourgeois M, et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double blind study. J Allergy Clin Immmol. 1996;98:14-20
17. Van Bever HP, Schuddinck L, Wojciechowski M, Stevens WJ. Aerosolized budesonide I in asthmatic infants: a double blind study. Pediatr Pulmonol. 1990;9:177-180
18. Pedersen S, Ramsgaard-Hansen O, Nikander K. Budesonide suspension for nebulisation in children with asthma. Eur Respir J. 1989;2:647S
19. Otulanda BA, Varma N, Bullock A, Higgenbottam T. High dose nebulized steroid in the treatment of chronic asthma. Respir Med. 1992;86: 105-108
20. National Heart, Lung and Blood Institute, National Institutes of Health. I. Definition and diagnosis. J Allergy Clin Immunol. 1991;88: 427-534
21. Polgar G, Promadhat V. Pulmonary Function Testing in Children. Techniques and Standards. Philadelphia, PA: WB Saunders Company; 1971; 254
22. Vikre-Jorgensen J, Agertoft L, Pedersen S. Dose titration of nebulized budesonide in young children. Pediatr Pulitionot. 1997;23:270-277
23. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid budesonide. J Allergy Clin Immunol. 1982;70:288-298
24. Malo JL, Cartier A, Merland N, et al. Four times a day dosing frequency is better than twice daily regimen in subjects who required a high- dose inhaled steroid, budesonide, to control moderate to severe asthma. Am Rev Respir Dis. 1989;190:624-628
25. Boulet LP, Stepner N, Robson R. Comparative efficacy of once vs twice daily dosing of inhaled fluticasone propionate in the management of mild and moderate asthma. Am J Respir Crit Care Med. 1997;155:A352
26. Mahajan P, Davis G, Field E. Asthma-specific quality of life improves following asthma treatment with fluticasone propionate powder 250 meg twice daily or 500 meg once daily. Am J Respir Crit Care Med. 1997;155:A349
27. Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled corticosteroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol. 1997;100:771-774
28. Jones AH, Langdon CG, Lee PS, et al. Pulmicort Turbuhaler once daily as initial prophylactic therapy for asthma. Respir Med. 1994;88: 293-299
29. Pincus DH, Szefler S, Akerson LM, Martin RJ. Chronotherapy of asthma with inhaled steroids: the effect of dosing timing on drug efficacy. J Allergy Clin Immunol. 1995;95:1172-1180
30. McFadden ER. Budesonide Turbuhaler once daily administration for patients with mild to moderate chronic asthma. Am J Respir Crit Care Med. 1997;155:A352
31. Varsano I, Volovitz B, Malik H, Amir Y. Safety of 1 year of treatment with budesonide in young children with asthma. J Allergy Clin Immunol. 1990;85:914-920
32. Kerrebijin KF, van Essen-Zandvliet EEM, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987;79:653-659
33. Ribeiro LB. Budesonide: safety and efficacy aspects of its long-term use in children. Pediatr Allergy Immunol. 1993;4:73-78
34. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled glucocorticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994;88:373-381
35. Price JF, Weller PH. Comparison of fluticasone propionate and sodium cromglycate for the treatment of childhood asthma (an open parallel group study). Respir Med. 1995;89:363-368
36. Kraemer R, Sennhauser F, Reinhardt M. Effects of regular inhalation of beclomethasone dipropionate and sodium cromoglycate on bronchial hyperreactiviry in asthmatic children. Acta Paediatr Scand. 1987;76: 119-123
37. Tasche MJA, zan der Wouden JC, Lijen JHJM, et al. Randomised placebo-controlled trial of inhaled sodium cromoglycate in 1-4-year-old children with moderate asthma. Lancet. 1997;350:1060-1064